Vaxil Bio Ltd.
VXL.V
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 128.04% | -45.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 125.33% | -45.22% | |||
| Operating Income | -125.33% | 45.22% | |||
| Income Before Tax | -210.83% | 56.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -210.83% | 56.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -210.83% | 56.27% | |||
| EBIT | -125.33% | 45.22% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -212.28% | 56.49% | |||
| Normalized Basic EPS | -208.33% | 56.10% | |||
| EPS Diluted | -212.28% | 56.49% | |||
| Normalized Diluted EPS | -208.33% | 56.10% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||